Nestlé explores new options with weight loss drugs

Nestlé is looking to open a new market for weight loss medications by investing in artificial intelligence and nutritional sciences, with the goal of developing products tailored for users of GLP-1 drugs like Ozempic and Wegovy. The company aims to analyze clinical research and identify nutritional formulations to support muscle health and reduce side effects associated with rapid weight loss, such as muscle and facial fat loss. Nestlé relies on AI tools to accelerate product development, including items that support muscle health and appetite reduction, and has already begun launching high-protein drinks to help compensate for muscle mass loss. The company considers this market to be a tremendous opportunity, given the significant increase in the number of people using weight loss medications, and plans to offer health solutions that address side effects and improve nutrition for consumers.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل